These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38619722)

  • 21. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.
    Isitt JJ; Roze S; Tilden D; Arora N; Palmer AJ; Jones T; Rentoul D; Lynch P
    Diabet Med; 2022 Jul; 39(7):e14831. PubMed ID: 35298036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.
    Reed J; Dong T; Eaton E; Friswold J; Porges J; Al-Kindi SG; Rajagopalan S; Neeland IJ
    Diabetes Obes Metab; 2024 Jul; 26(7):2881-2889. PubMed ID: 38680050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study.
    Gilbert TR; Noar A; Blalock O; Polonsky WH
    Diabetes Technol Ther; 2021 Mar; 23(S1):S35-S39. PubMed ID: 33470882
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
    Misurski D; Lage MJ; Fabunmi R; Boye KS
    Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
    Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
    Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization.
    Aagren M; Luo W; Moës E
    J Med Econ; 2010 Mar; 13(1):16-22. PubMed ID: 19958212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
    Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
    J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations.
    Annavarapu S; Ghosh S; Li Y; Moretz C; Shetty S; Prewitt T
    Am J Manag Care; 2020 Jun; 26(6):e166-e171. PubMed ID: 32549065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
    Pelletier EM; Smith PJ; Boye KS; Misurski DA; Tunis SL; Minshall ME
    Appl Health Econ Health Policy; 2008; 6(2-3):103-12. PubMed ID: 19231904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States.
    Bajpai S; Wong-Jacobson S; Liu D; Mitchell B; Haynes G; Syring K; Ali AK; Chinthammit C
    J Manag Care Spec Pharm; 2021 Mar; 27(3):385-391. PubMed ID: 33645242
    [No Abstract]   [Full Text] [Related]  

  • 35. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
    McCoy RG; Lipska KJ; Van Houten HK; Shah ND
    JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of insulin initiation on resource utilization and direct costs of treatment over 12 months in patients with type 2 diabetes in Europe: results from INSTIGATE and TREAT observational studies.
    Brismar K; Benroubi M; Nicolay C; Schmitt H; Giaconia J; Reaney M
    J Med Econ; 2013 Aug; 16(8):1022-35. PubMed ID: 23738910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
    Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
    Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment satisfaction and quality of life for an integrated continuous glucose monitoring/insulin pump system compared to self-monitoring plus an insulin pump.
    Rubin RR; Peyrot M
    J Diabetes Sci Technol; 2009 Nov; 3(6):1402-10. PubMed ID: 20144395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.